The Combined Oral Contraceptive Pill in Women Over Age Forty

Annals of the Academy of Medicine Singapore

Volumn 32, Issue 5, 2003, Pages 624-631

  Wong, M T ^a   Singh, Kuldip ^a  

^a NATIONAL UNIVERSITY HOSPITAL   (Singapore)

Author keywords

Benefits; Contraception; Menopause; Osteoporosis; Risks

Indexed keywords

DESOGESTREL; DESOGESTREL PLUS ETHINYLESTRADIOL; ESTROGEN; ETHINYLESTRADIOL PLUS LEVONORGESTREL; ETHINYLESTRADIOL PLUS NORGESTIMATE; GESTODENE; LEVONORGESTREL; ORAL CONTRACEPTIVE AGENT; OSTEOCALCIN; PLACEBO; VIRUS DNA;

ACUTE HEART INFARCTION; ADULT; AGE; AGING; BONE DENSITY; BONE MINERAL; BRAIN EMBOLISM; BRAIN INFARCTION; BREAST CANCER; BREAST TUMOR; CANCER RISK; CLINICAL TRIAL; COHORT ANALYSIS; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DECISION MAKING; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; ECTOPIC PREGNANCY; ENDOMETRIUM CANCER; FEMALE; HIP FRACTURE; HORMONAL CONTRACEPTION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MELANOMA; MENOPAUSE; MENSTRUAL CYCLE; META ANALYSIS; METRORRHAGIA; MULTICENTER STUDY; ORAL CONTRACEPTION; OVARY CANCER; PELVIC INFLAMMATORY DISEASE; PILL; POSTMENOPAUSE OSTEOPOROSIS; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SINGAPORE; THROMBOEMBOLISM; UTERINE CERVIX CANCER; UTERINE CERVIX TUMOR; UTERUS BLEEDING; VASOMOTOR DISORDER; VIRUS CARCINOGENESIS; WART VIRUS;

EID: 0242635897     PISSN: 03044602     EISSN: 29724066     Source Type: Journal    
DOI: None     Document Type: Review

References (55)

1. Tessler S L, Peipert J F. Perceptions of contraceptive effectiveness and health effects of oral contraception. Women's Health Issues 1997; 7: 400-6.
2. Ortho Pharmaceutical. Ortho 1999 Annual birth control study. Raritan: Ortho Pharmaceutical, 1999.
3. Henshaw S K. Unintended pregnancy in the United States. Fam Plann Perspect 1998; 30:24-9.
4. Gambacciani M, Ciaponi M, Cappagli B, Benussi C, Genazzani A R. Longitudinal evaluation of perimenopausal femoral bone loss: effects of a low-dose oral contraceptive preparation on bone mineral density and metabolism. Osteoporos Int 2000; 11:544-8.
5. Gambacciani M, Spinetti A, Taponeco F, Cappagli B, Piaggesi L, Fioretti P. Longitudinal evaluation of perimenopausal vertebral bone loss: effects of a low-dose oral contraceptive preparation on bone mineral density and metabolism. Obstet Gynecol 1994; 83:392-6.
6. Volpe A, Malmusi S, Zanni A L, Landi S, Cagnacci A. Oral contraceptives and bone metabolism. Eur J Contracept Reprod Health Care 1997; 2: 225-8.
7. DeCherney A. Bone-sparing properties of oral contraceptives. Am J Obstet Gynecol 1996; 174:15-20.
8. Corson S L. Oral contraceptives for the prevention of osteoporosis. J Reprod Med 1993; 38:1015-20.
9. Lindsay R, Tohme J, Kanders B. The effect of oral contraceptive use on vertebral bone mass in pre- and post-menopausal women. Contraception 1986; 34:333-40.
10. Kuohung W, Borgatta L, Stubblefield P. Low-dose oral contraceptives and bone mineral density: an evidence-based analysis. Contraception 2000; 61:77-82.
11. Michaelsson K, Baron J A, Farahmand B Y, Persson I, Ljunghall S. Oral contraceptive use and risk of hip fracture: a case-control study. Lancet 1999; 353:1481-4.
12. Rossouw J E, Anderson G L, Prentice R L, LaCroix A Z, Kooperberg C, Stefanick M L, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288:321-33.
13. Davis A, Godwin A, Lippman J, Olson W, Kafrissen M. Triphasic norgestimate-ethinyl estradiol for treating dysfunctional uterine bleeding. Obstet Gynecol 2000; 96:913-20.
14. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development. The reduction in risk of ovarian cancer associated with oral contraceptive use. N Engl J Med 1987; 316:650-5.
15. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development. Combination oral contraceptive use and the risk of endometrial cancer. JAMA 1987; 257:796-800.
16. Modan B, Hartge P, Hirsh-Yechezkel G, Chetrit A, Lubin F, Beller U, et al. Parity, oral contraceptives and the risk of ovarian cancer among carriers and non-carriers of a BRCA1 or BRCA2 mutation. N Engl J Med 2001; 345:235-40.
17. Shargil A A. Hormone replacement therapy in perimenopausal women with a triphasic contraceptive compound: a three-year prospective study. Int J Fertil 1985; 30:15-28.
18. Fernandez E, La Vecchia C, Balducci A, Chatenoud L, Franceschi S, Negri E. Oral contraceptives and colorectal cancer risk: a meta-analysis. Br J Cancer 2001; 84:722-7.
19. Drossaers-Bakker K W, Zwinderman A H, van Zeben D, Breedveld F C, Hazes J M. Pregnancy and oral contraceptive use do not significantly influence outcome in long-term rheumatoid arthritis. Ann Rheum Dis 2002; 61:405-8.
20. Spector T D, Hochberg M C. The protective effect of the oral contraceptive pill on rheumatoid arthritis: an overview of the analytic epidemiological studies using meta-analysis. J Clin Epidemiol 1990; 43:1221-30.
21. Franks A L, Beral V, Cates W Jr, Hogue C J. Contraception and ectopic pregnancy risk. Am J Obstet Gynecol 1990; 163:1120-3.
22. Panser L A, Phipps W R. Type of oral contraceptive in relation to acute, initial episodes of pelvic inflammatory disease. Contraception 1991; 43:91-9.
23. Wolner-Hanssen P, Eschenbach D A, Paavonen J, Kiviat N, Stevens C E, Critchlow C, et al. Decreased risk of symptomatic Chlamydial pelvic inflammatory disease associated with oral contraceptive use. JAMA 1990; 263:54-9.
24. Schwingl P J, Ory H W, Visness C M. Estimates of the risk of cardiovascular death attributable to low-dose oral contraceptives in the United States. Am J Obstet Gynecol 1999; 180:24-9.
25. World Health Organization Scientific Group on Cardiovascular Disease and Steroid Hormone Contraception. Cardiovascular disease and steroid hormone contraception: a report of a WHO Scientific Group. Geneva: World Health Organization, 1998. Technical Report Series No. 877.
26. National Institutes of Health Consensus Development Conference. Prevention of venous thrombosis and pulmonary embolism. JAMA 1986; 256:744-9.
27. Gherman R B, Goodwin T M, Leung B, Byrne J D, Hethumumi R, et al. Incidence, clinical characteristics, and timing of objectively diagnosed venous thromboembolism during pregnancy. Obstet Gynecol 1999; 94:730-4.
28. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. Lancet 1995; 346:1575-82.
29. Spitzer W O, Lewis M A, Heinemann L A, Thorogood M, MacRae K D. Third-generation oral contraceptives and risk of venous thromboembolic disorders:an international case-control study. Transnational Research Group on Oral Contraceptives and the Health of Young Women. BMJ 1996; 312:83-8.
30. Jick H, Jick S S, Gurewich V, Myers M W, Vasilakis C. Risk of idiopathic cardiovascular death and non-fatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 1995; 346:1589-93.
31. Lawrenson R, Farmer R. Venous thromboembolism and combined oral contraceptives: does the type of progestagen make a difference? Contraception 2000; 62:S21-S28.
32. Kaper R F, Norpoth T, Rekers H. Third- and second-generation oral contraceptives are associated with similar risks estimates for venous thromboembolism. Eur J Contracept Reprod Health Care 2000; 5:1-15.
33. Suissa S, Blais L, Spitzer W O, Cusson J, Lewis M, Heinemann L. First-time use of newer oral contraceptives and the risk of venous thromboembolism. Contraception 1997; 56:141-6.
34. Kemmeren J M, Algra A, Grobbee D E. Third generation oral contraceptives and risk of venous thrombosis: meta-analysis. BMJ 2001; 323:131-4.
35. Suissa S, Spitzer W O, Rainville B, Cusson J, Lewis M, Heinemann L. Recurrent use of newer oral contraceptives and the risk of venous thromboembolism. Hum Reprod 2000; 15:817-21.
36. Petitti D B, Sidney S, Bernstein A, Wolf S, Quesenberry C, Ziel H K. Stroke in users of low-dose oral contraceptives. N Engl J Med 1996; 335:8-15.
37. Schwartz S M, Siscovick D S, Longstreth W T Jr, Psaty B M, Beverly R K, Raghunathan T E, et al. Use of low-dose oral contraceptives and stroke in young women. Ann Intern Med 1997; 127:596-603.
38. Schwartz S M, Petitti D B, Siscovick D S, Longstreth W T Jr, Sidney S, Raghunathan T E, et al. Stroke and use of low-dose oral contraceptives in young women: a pooled analysis of two US studies. Stroke 1998; 29:2277-84.
39. Heinemann L A, Lewis M A, Thorgood M, Spitzer W O, Guggenmoos-Holzmann I, Bruppacher R. Case-control study of oral contraceptives and risk of thromboembolic stroke: results from International Study on Oral Contraceptives and Health of Young Women. BMJ 1997; 315: 1502-4.
40. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Ischaemic stroke and combined oral contraceptives: results of an international, multicentre, case-control study. Lancet 1996; 348:498-505.
41. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Haemorrhagic stroke, overall stroke risk and combined oral contraceptives: results of an international, multicentre, case-control study. Lancet 1996; 348:505-10.
42. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Acute myocardial infarction and combined oral contraceptives: results of an international multicentre, case-control study. Lancet 1997; 349:1202-9.
43. Sidney S, Siscovick D S, Petitti D B, Schwartz S M, Quesenberry C P, Psaty B M, et al. Myocardial infarction and use of low-dose oral contraceptives: a pooled analysis of 2 US studies. Circulation 1998; 98:1058-63.
44. Tanis B C, van den Bosch M A, Kemmeren J M, Cats V M, Helmerhorst F M, Algra A, et al. Oral contraceptives and the risk of myocardial infarction. N Engl J Med 2001; 345:1787-93.
45. Collaborative Group on Hormone Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative re-analysis of individual data on 53,297 women with breast cancer and 100,239 women without breast cancer from 54 epidemiological studies. Lancet 1996; 347:713-27.
46. Marchbanks P A, McDonald J A, Wilson H G, Folger S G, Mandel M G, Daling J R, et al. Oral contraceptives and the risk of breast cancer. N Engl J Med 2002; 346:2025-32.
47. Karagas M R, Stukel T A, Dykes J, Miglionico J, Greene M A, Carey M, et al. A pooled analysis of 10 case-control studies of melanoma and oral contraceptive use. Br J Cancer 2002; 86:1085-92.
48. Smith J S, Green J, Berrington de Gonzalez A, Appleby P, Peto J, Plummer M, et al. Cervical cancer and use of hormonal contraceptives: a systematic review. Lancet 2003; 361:1159-67.
49. Moreno V, Bosch F X, Munoz N, Meijer C, Shah K V, Walboomers J, et al, for the International Agency for Research on Cancer (IARC) Multicentric Cervical Cancer Study Group. Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: the IARC multicentric case-control study. Lancet 2002; 359:1085-92.
50. Beral V, Hermon C, Kay C, Hannaford P, Darby S, Reeves G. Mortality associated with oral contraceptive use: 25-year follow-up of cohort of 46,000 women from Royal College of General Practitioners' oral contraception study. BMJ 1999; 318:96-100.
51. Munoz N, Franceschi S, Bosetti C, Moreno V, Herrero R, Smith J S, et al, for the International Agency for Research on Cancer (IARC) Multicentric Cervical Cancer Study Group, Role of parity and human papillomavirus in cervical cancer: the IARC multicentric case-control study. Lancet 2002; 359:1093-101.
52. Green J, Berrington de Gonzalez A, Smith J S, Franceschi S, Appleby P, Plummer M, et al. Human papillomavirus infection and use of oral contraceptives. Br J Cancer 2003; 88:1713-20.
53. de Villiers E M. Relationship between steroid hormone contraception and HPV, cervical intraepithelial neoplasia and cervical cancer. Int J Cancer 2003; 103:705-8.
54. Moodley M, Moodley J, Chetty R, Herrington C S. The role of steroid contraceptive hormones in the pathogenesis of invasive cervical cancer: a review. Int J Gynecol Cancer 2003; 13:103-10.
55. Schlesselman J J. Net effect of oral contraceptive use on the risk of cancer in women in the United States. Obstet Gynecol 1995; 85:793-801.